Difference between revisions of "Talk:Programmed death-ligand 1"

Jump to navigation Jump to search
no edit summary
Line 7: Line 7:
*2018 paper: ~ 70% durable response among those that discontinue d/t side effects[https://www.ncbi.nlm.nih.gov/pubmed/29437040]
*2018 paper: ~ 70% durable response among those that discontinue d/t side effects[https://www.ncbi.nlm.nih.gov/pubmed/29437040]
*2018 paper: response rates are low in UCC and RCC, current PD-L1 tests not useful in UCC and RCC[https://www.ncbi.nlm.nih.gov/pubmed/29368638]
*2018 paper: response rates are low in UCC and RCC, current PD-L1 tests not useful in UCC and RCC[https://www.ncbi.nlm.nih.gov/pubmed/29368638]
==References==
{{Reflist|1}}
48,466

edits

Navigation menu